Tempus AI announced positive results from a large study. The study focused on its AI-enabled pre-screening panel for advanced non-small cell lung cancer (NSCLC). Tempus AI presented the data at the European Society for Medical Oncology (ESMO) Congress. The study involved over 60,000 cancer cases. The AI tool achieved over 80% sensitivity. It identified 12 key biomarkers from pathology images.
The panel helps clinicians prioritize and accelerate biomarker testing. This is crucial for selecting targeted therapies. By analyzing routine pathology slides, the AI helps preserve limited tumor tissue. It also ensures more patients receive appropriate and timely testing. The study involved an ongoing collaboration with Pfizer. The pre-screening panel remains in development. It is not intended to replace current testing methods.